Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis

Gynecologic Oncology

Volumn 100, Issue 3, 2006, Pages 591-595

  Tsai, Ching Chou ^a   Liu, Yi Shan ^b   Huang, Eng Yen ^a   Huang, Shun Chen ^a   Chang, Hsueh Wen ^c   Tseng, Chih Weng ^a   ChangChien, Chan Chao ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

CA125; Cervical adenocarcinoma; Histopathological prognostic factors; Radical hysterectomy

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; STATISTICAL SIGNIFICANCE; STROMA; TUMOR VOLUME; UTERINE CERVIX CANCER;

ADENOCARCINOMA; CA-125 ANTIGEN; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 32644470597     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.09.049     Document Type: Article

References (30)

1. H.O. Smith, M.F. Tiffany, C.R. Qualls, and C.R. Key The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-A 24-year population-based study Gynecol. Oncol. 78 2000 97 105
2. D.P. Bender, J.I. Sorosky, R.E. Buller, and A.K. Sood Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma Am. J. Obstet. Gynecol. 189 2003 113 117
3. R.C. Bast Jr., T.L. Klug, E. St John, E. Jenison, J.M. Niloff, and H. Lazarus A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N. Engl. J. Med. 309 1983 883 887
4. J.M. Niloff, T.L. Klug, E. Schaetzl, V.R. Zurawski Jr., R.C. Knapp, and R.C. Bast Jr. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix Am. J. Obstet. Gynecol. 148 1984 1057 1058
5. J.M. Duk, J.G. Aalders, G.J. Fleuren, M. Krans, and H.W. De Bruijn Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix Obstet. Gynecol. 73 1989 661 668
6. R.E. Buller, M.L. Berman, J.D. Bloss, A. Manetta, and P.J. DiSaia Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival Gynecol. Oncol. 47 1992 87 92
7. A.K. Sood, R.E. Buller, R.A. Burger, J.D. Dawson, J.I. Sorosky, and M. Berman Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome Obstet. Gynecol. 90 1997 441 447
8. B.C. Cooper, A.K. Sood, C.S. Davis, J.M. Ritchie, J.I. Sorosky, and B. Anderson 125 levels: an independent prognostic factor for epithelial ovarian cancer Obstet. Gynecol. 100 2002 59 64
9. P. Lehtovirta, L. Viinikka, and O. Ylikorkala Comparison between squamous cell carcinoma-associated antigen and CA-125 in patients with carcinoma of the cervix Gynecol. Oncol. 37 1990 276 278
10. A. Leminen Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma Gynecol. Oncol. 39 1990 358 363
11. G. Borras, R. Molina, J. Xercavins, A. Ballesta, and J. Iglesias Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix Gynecol. Oncol. 57 1995 205 211
12. H.Y. Ngan, A.N. Cheung, I.J. Lauder, L.C. Wong, and H.K. Ma Prognostic significance of serum tumour markers in carcinoma of the cervix Eur. J. Gynaecol. Oncol. 17 1996 512 517
13. T. Alagoz, R.E. Buller, M. Berman, B. Anderson, A. Manetta, and P. DiSaia What is a normal CA125 level? Gynecol. Oncol. 53 1994 93 97
14. G. Delgado Stage IB squamous cancer of the cervix: the choice of treatment Obstet. Gynecol. Surv 33 1978 174 183
15. T.W. Burke, W.J. Hoskins, P.B. Heller, M.C. Bibro, E.B. Weiser, and R.C. Park Prognostic factors associated with radical hysterectomy failure Gynecol. Oncol. 26 1987 153 159
16. A.F. Fuller Jr., N. Elliott, C. Kosloff, W.J. Hoskins, and J.L. Lewis Jr. Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix Gynecol. Oncol. 33 1989 34 39
17. G. Delgado, B. Bundy, R. Zaino, B.U. Sevin, W.T. Creasman, and F. Major Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study Gynecol. Oncol. 38 1990 352 357
18. A. Sedlis, B.N. Bundy, M.Z. Rotman, S.S. Lentz, L.I. Muderspach, and R.J. Zaino A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study Gynecol. Oncol. 73 1999 177 183
19. A. Obermair, C. Wanner, S. Bilgi, P. Speiser, K. Reisenberger, and A. Kaider The influence of vascular space involvement on the prognosis of patients with stage IB cervical carcinoma: correlation of results from hematoxylin and eosin staining with results from immunostaining for factor VIII-related antigen Cancer 82 1998 689 696
20. V. Kumar, A.K. Abbas, and N. Fausto Pathologic Basis of Disease 2005 Saunders, Inc. Philadelphia 513
21. W.T. Creasman, and M.F. Kohler Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? Gynecol. Oncol. 92 2004 525 529 [Review]
22. P. Sykes, D. Allen, C. Cohen, J. Scurry, and D. Yeo Does the density of lymphatic vascular space invasion affect the prognosis of stage Ib and IIA node negative carcinoma of the cervix? Int. J. Gynecol. Cancer 13 2003 313 316
23. R.A.K. Samlal, J. van der Velden, F.J. Ten Kate, M.S. Schilthuis, A.A. Hart, and F.B. Lammes Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes Cancer 80 1997 1234 1240
24. N. Sakuragi, C. Satoh, N. Takeda, H. Hareyama, M. Takeda, and R. Yamamoto Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy Cancer 85 1999 1547 1554
25. H. Hricak, C.G. Lacey, L.G. Sandles, Y.C. Chang, M.L. Winkler, and J.L. Stern Invasive cervical carcinoma: comparison of MR imaging and surgical findings Radiology 166 1988 623 631
26. M. Follen, C.F. Levenback, R.B. Iyer, P.W. Grigsby, E.A. Boss, and E.S. Delpassand Imaging in cervical cancer Cancer 98 2003 2028 2038
27. A. Baalbergen, P.C. Ewing-Graham, W.C. Hop, P. Struijk, and T.J. Helmerhorst Prognostic factors in adenocarcinoma of the uterine cervix Gynecol. Oncol. 92 2004 262 267
28. F. Landoni, A. Maneo, A. Colombo, F. Placa, R. Milani, and P. Perego Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer Lancet 350 1997 535 540
29. H.S. Ryu, M. Chun, K.H. Chang, H.J. Chang, and J.P. Lee Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients Gynecol. Oncol. 96 2 2005 490 495
30. D.K. Pauler, U. Menon, M. McIntosh, H.L. Symecko, S.J. Skates, and I.J. Jacobs Factors influencing serum CA125II levels in healthy postmenopausal women Cancer Epidemiol. Biomarkers Prev. 10 5 2001 489 493